Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR20013 vs fosaprepitant for prevention of cisplatin-induced nausea and vomiting
CTR20222107Phase 3Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rolapitant + palonosetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Overall complete response rate in cycle 1 (0–120 h). Started Aug 2022; status: completed.
02
Drugs
rolapitant + palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on CTR20222107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222107.